Author

C. Prelli Bozzo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1

Frequent Co-Authors

F. Kirchhoff· 6 shared F. Zech· 5 shared L. Koepke· 5 shared R. Nchioua· 5 shared K. M. J. Sparrer· 4 shared A. Graf· 3 shared D. Kmiec· 3 shared H. Blum· 3 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersMicrobiology

F. Kirchhoff

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Traitor-virus-guided discovery of novel antiviral factors

C. Prelli Bozzo, A. Laliberte, A. De Luna, C. Pastorio, K. Regensburger, S. Krebs, A. Graf, H. Blum, M. Volcic, K. M. Sparrer, F. Kirchhoff

This study uses HIV-guided CRISPR to identify antiviral factors by analyzing sgRNA enrichment during viral replication.

bioRxiv · Nov 3, 2023 · PreprintMicrobiology

SARS-CoV-2 variants of concern are dependent on IFITM2 for efficient replication in human lung cells

R. Nchioua, A. Schundner, D. Kmiec, C. Prelli Bozzo, F. Zech, L. Koepke, A. Graf, S. Krebs, H. Blum, M. Frick, K. M. J. Sparrer, F. Kirchhoff

The paper was withdrawn due to duplicate submission and is not intended for citation.

bioRxiv · Dec 6, 2021 · PreprintImmunology

SARS-CoV-2 variants of concern remain dependent on IFITM2 for efficient replication in human lung cells

R. Nchioua, A. Schundner, D. Kmiec, C. Prelli Bozzo, F. Zech, L. Koepke, A. Graf, S. Krebs, H. Blum, M. Frick, K. M. Sparrer, F. Kirchhoff

This study shows that SARS-CoV-2 variants of concern (VOCs) require IFITM2 for efficient replication in human lung cells, with IFITM2 depletion reducing viral RNA and infectious virus production by over four orders of magnitude.

bioRxiv · Nov 17, 2021 · PreprintMicrobiology

Spike mutation T403R allows bat coronavirus RaTG13 to use human ACE2

F. Zech, D. Schniertshauer, C. Jung, A. Herrmann, Q. Xie, R. Nchioua, C. Prelli Bozzo, M. Volcic, L. Koepke, J. Krueger, S. Heller, A. Kleger, T. Jacob, K.-K. Conzelmann, A. Ensser, , F. Kirchhoff

The paper shows that a single amino acid mutation in the Spike protein of bat coronavirus RaTG13 enables it to use human ACE2 for infection.

bioRxiv · May 31, 2021 · PreprintMicrobiology

Imperfect innate immune antagonism renders SARS-CoV-2 vulnerable towards IFN-γ and -{lambda}

M. Hayn, M. Hirschenberger, L. Koepke, J. H. Straub, R. Nchioua, M. H. Christensen, S. Klute, C. Prelli Bozzo, W. Aftab, F. Zech, C. Conzelmann, J. A. Mueller, S. Srinivasachar Badarinarayan, C. M. Stuerzel, I. Forne, , K. M. J. Sparrer

This study identifies SARS-CoV-2's vulnerability to IFN-γ and -λ due to its inefficient antagonism of type I and II IFN responses, suggesting potential therapeutic strategies.

bioRxiv · Oct 15, 2020Microbiology

IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition

C. Prelli Bozzo, R. Nchioua, M. Volcic, J. Krueger, S. Heller, C. M. Stuerzel, D. Kmiec, C. Conzelmann, J. A. Mueller, F. Zech, D. Schuetz, L. Koepke, E. Braun, R. Gross, L. Wettstein, , F. Kirchhoff

This study shows that IFITM proteins are required for SARS-CoV-2 infection and can be targeted to inhibit viral entry and replication.

bioRxiv · Aug 18, 2020 · PreprintMicrobiology